Literature DB >> 188388

Stimulation by melanocyte stimulating hormone and dibutyryl adenosine 3'5'-cyclic monophosphate of DNA synthesis in human melanocytes in vitro.

Y Kitano.   

Abstract

The proliferation of human melanocytes in vitro was stimulated by MSH. This stimulation was further intensified by the simultaneous addition of theophylline with MSH. Theophylline alone stimulated proliferation moderately. Dibutyryl cyclic AMP strongly stimulated the proliferation, but sodium butyrate, 5'-AMP and cGMP did not. The stimulation by dibutyryl cyclic AMP was continued up to 4 days so far tested. These findings are directly opposed to those on mouse melanoma cells in culture which responded with retarded growth to MSH and cyclic AMP. It is suggested that the difference of proliferation control may explain the different reaction of the melanocyte and the melanoma cells. The epidermal melanocytes seem to belong to the exceptional group of the cells which responded to cyclic AMP with accelerated proliferation.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 188388     DOI: 10.1007/bf00569112

Source DB:  PubMed          Journal:  Arch Dermatol Res            Impact factor:   3.017


  26 in total

1.  Effect of the melanocyte stimulating hormone of the pituitary on melanocytes and melanin in the skin of guinea-pigs.

Authors:  R S SNELL
Journal:  J Endocrinol       Date:  1962-10       Impact factor: 4.286

2.  Human melanogenesis; cytology and histology of pigment cells (melanodendrocytes).

Authors:  S W BECKER; T B FITZPATRICK; H MONTGOMERY
Journal:  AMA Arch Derm Syphilol       Date:  1952-05

3.  Mitotic division of human dendritic melanoblasts.

Authors:  H PINKUS
Journal:  J Invest Dermatol       Date:  1949-12       Impact factor: 8.551

4.  Cyclic adenosine 3',5'-monophosphate in the control of melanoma cell replication and differentiation.

Authors:  J W Kreider; M Rosenthal; N Lengle
Journal:  J Natl Cancer Inst       Date:  1973-02       Impact factor: 13.506

5.  Dibutyryl cyclic AMP inhibition of epidermal cell division.

Authors:  J J Voorhees; E A Duell; W H Kelsey
Journal:  Arch Dermatol       Date:  1972-03

6.  Effect of pharmacological agents on human keratinocyte mitosis in vitro. I. Inhibition by adenine nucleotides.

Authors:  R A Harper; B A Flaxman; D P Chopra
Journal:  Proc Soc Exp Biol Med       Date:  1974-09

7.  Studies on the mechanism of hormonal induction of the melanoblast-melanocyte transformation in organ culture.

Authors:  C D Foote; T T Tchen
Journal:  Exp Cell Res       Date:  1967-09       Impact factor: 3.905

8.  Hormonal induction of melanogenesis in hypophysectomized killifish (Fundulus heteroclitus).

Authors:  G E PICKFORD; B KOSTO
Journal:  Endocrinology       Date:  1957-08       Impact factor: 4.736

9.  Restoration of contact-inhibited growth to transformed cells by dibutyryl adenosine 3':5'-cyclic monophosphate.

Authors:  J R Sheppard
Journal:  Proc Natl Acad Sci U S A       Date:  1971-06       Impact factor: 11.205

10.  Inhibition of growth and DNA synthesis in cell cultures by cyclic AMP.

Authors:  P Eker
Journal:  J Cell Sci       Date:  1974-11       Impact factor: 5.285

View more
  4 in total

1.  Selective proliferation of normal human melanocytes in vitro in the presence of phorbol ester and cholera toxin.

Authors:  M Eisinger; O Marko
Journal:  Proc Natl Acad Sci U S A       Date:  1982-03       Impact factor: 11.205

2.  Biological and biochemical properties of a human uveal melanocyte-derived cell line.

Authors:  F L Meyskens; E B Berglund; D F Saxe; B B Fuller; L Z Pacelli; J D Hall; C G Ray
Journal:  In Vitro       Date:  1980-09

3.  Successful establishment of uveal and conjunctival melanoma in vitro.

Authors:  M McNamara; S M Kennedy
Journal:  In Vitro Cell Dev Biol Anim       Date:  1997-04       Impact factor: 2.723

4.  Modulation of clonogenic human melanoma cells by follicle-stimulating hormone, melatonin, and nerve growth factor.

Authors:  F L Meyskens; S E Salmon
Journal:  Br J Cancer       Date:  1981-01       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.